CaseBioscience and Team Receive $7.3 Million to Enhance Cell Therapy Storage
In a remarkable advancement in biotechnology, CaseBioscience® announced its collaboration with a multidisciplinary team led by Likarda, which has recently received an impressive grant of up to $7.3 million from the Advanced Research Projects Agency for Health (ARPA-H). This funding is allocated under the BioStabilization Systems (BoSS) program, aimed at revolutionizing the preservation and transportation of cell therapies. The primary goal of this initiative is to develop innovative technologies that allow living cells to be stored and transported at room temperature, eliminating the need for refrigeration.
The BoSS program supports research that seeks to remove the complexities and costs associated with cold-chain logistics essential for maintaining cell viability. Many current cell-based medical products depend on specialized environments to ensure their effectiveness. However, if solutions for ambient storage can be developed, it could lead to significant advancements in the accessibility of these advanced therapies. As elucidated by ARPA-H, their ambition is to make biologics as easy to store and transport as common pharmaceuticals like aspirin.
The Reversible Ambient Biostabilization (RAB) team, chosen as one of only three teams for this esteemed program, harnesses a wealth of expertise that spans multiple scientific domains, including preservation science, bioengineering, cellular biology, and immunology. The team consists of prominent organizations such as Draper, CPSI Biotech, Fresenius Kabi, MiNK Therapeutics, and the Spencer Lab at the University of Colorado Boulder, each bringing their specialized knowledge to the table.
- Project Name: Reversible Ambient Biostabilization
- Funding Amount: Up to $7.3 million
- Duration: Initial phase of 15 months starting from September 24, 2026
By integrating specialized physiological strategies along with state-of-the-art bioengineering techniques, the RAB team plans to pioneer practical ways for the ambient storage and transportation of cellular therapies. This shift could substantially reduce dependency on current logistics, making cell therapies available to a broader audience and paving the way for further innovations in health care.
Dr. John Baust, a pivotal figure in biopreservation, expressed optimism about the project, noting the long history of attempts to preserve living cells effectively. "ARPA-H's BoSS program is offering a unique opportunity to tackle this challenge through a multi-disciplinary approach, potentially signaling a new era in biopharmaceutical logistics," he stated.
CaseBioscience touts extensive experience in clinical media formulation, biopreservation, and cellular metabolism, which will greatly contribute to the development of novel techniques for ambient stabilization of therapeutic cells. Dr. Lynda McGinnis, a prominent researcher within CaseBioscience, highlighted the company’s historical connection to biopreservation research, stating, "We're revisiting concepts that have laid the groundwork for today's innovations. This opportunity has the potential to redefine how clinical therapies and even reproductive medicine manage cell preservation."
Now, with funding in hand and a dedicated team assembled, CaseBioscience, under the leadership of Chief Scientific Officer Dr. Kevin Flynn, is geared up to explore unprecedented approaches and advancements in the field. Dr. Flynn voiced their excitement at being part of this significant program and noted the potential impact on the future of biological therapies.
Ami Mezezi, Co-Founder and Managing Director of CaseBioscience, remarked, "Being selected for ARPA-H's BoSS program is a significant recognition of our innovative preservation technology. It reaffirms our commitment to making living cell therapies more accessible at a global scale."
As the RAB team's research efforts commence, the implications of successfully developing ambient preservation technologies could reshape the landscape of cell therapies significantly. The commitment of CaseBioscience, in collaboration with leading organizations in the field, could soon transform the future of cellular medicine and bring breakthroughs within reach for patients around the world. Stay tuned for further updates from this exciting venture into the realm of biopreservation and cell therapy logistics.
Background of the Initiative
The BoSS program supports research that seeks to remove the complexities and costs associated with cold-chain logistics essential for maintaining cell viability. Many current cell-based medical products depend on specialized environments to ensure their effectiveness. However, if solutions for ambient storage can be developed, it could lead to significant advancements in the accessibility of these advanced therapies. As elucidated by ARPA-H, their ambition is to make biologics as easy to store and transport as common pharmaceuticals like aspirin.
Key Project Highlights
The Reversible Ambient Biostabilization (RAB) team, chosen as one of only three teams for this esteemed program, harnesses a wealth of expertise that spans multiple scientific domains, including preservation science, bioengineering, cellular biology, and immunology. The team consists of prominent organizations such as Draper, CPSI Biotech, Fresenius Kabi, MiNK Therapeutics, and the Spencer Lab at the University of Colorado Boulder, each bringing their specialized knowledge to the table.
- - Program Overview
- Project Name: Reversible Ambient Biostabilization
- Funding Amount: Up to $7.3 million
- Duration: Initial phase of 15 months starting from September 24, 2026
The Promise of Ambient Storage
By integrating specialized physiological strategies along with state-of-the-art bioengineering techniques, the RAB team plans to pioneer practical ways for the ambient storage and transportation of cellular therapies. This shift could substantially reduce dependency on current logistics, making cell therapies available to a broader audience and paving the way for further innovations in health care.
Dr. John Baust, a pivotal figure in biopreservation, expressed optimism about the project, noting the long history of attempts to preserve living cells effectively. "ARPA-H's BoSS program is offering a unique opportunity to tackle this challenge through a multi-disciplinary approach, potentially signaling a new era in biopharmaceutical logistics," he stated.
The Role of CaseBioscience
CaseBioscience touts extensive experience in clinical media formulation, biopreservation, and cellular metabolism, which will greatly contribute to the development of novel techniques for ambient stabilization of therapeutic cells. Dr. Lynda McGinnis, a prominent researcher within CaseBioscience, highlighted the company’s historical connection to biopreservation research, stating, "We're revisiting concepts that have laid the groundwork for today's innovations. This opportunity has the potential to redefine how clinical therapies and even reproductive medicine manage cell preservation."
Now, with funding in hand and a dedicated team assembled, CaseBioscience, under the leadership of Chief Scientific Officer Dr. Kevin Flynn, is geared up to explore unprecedented approaches and advancements in the field. Dr. Flynn voiced their excitement at being part of this significant program and noted the potential impact on the future of biological therapies.
Ami Mezezi, Co-Founder and Managing Director of CaseBioscience, remarked, "Being selected for ARPA-H's BoSS program is a significant recognition of our innovative preservation technology. It reaffirms our commitment to making living cell therapies more accessible at a global scale."
Conclusion
As the RAB team's research efforts commence, the implications of successfully developing ambient preservation technologies could reshape the landscape of cell therapies significantly. The commitment of CaseBioscience, in collaboration with leading organizations in the field, could soon transform the future of cellular medicine and bring breakthroughs within reach for patients around the world. Stay tuned for further updates from this exciting venture into the realm of biopreservation and cell therapy logistics.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.